Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT04361370 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer

Interventions

DRUG: Olaparib-Pembrolizumab-Bevacizumab

Sponsor

Yonsei University